Alpha Teknova’s third-quarter revenue rose 22% year over year to $12.70 million, above the $11.64 million analyst estimate. The company raised its 2026 revenue outlook to $46 million-$48 million and maintained its forecast for free cash outflow below $8 million.
Third-quarter revenue increased 22% year over year to $12.70 million, beating the $11.64 million analyst estimate. The company said growth was driven by increased sales to life science tools and diagnostics, and biopharma customers, including higher purchases of custom products by small and midsized biotech firms and their contract manufacturers.
Alpha Teknova raised its 2026 revenue guidance to $46 million-$48 million and maintained its free cash outflow guidance at less than $8 million. Clinical Solutions revenue rose 86% year over year, while gross margin increased to 38.0% from 30.7%, mainly due to higher revenue and lower fixed cost absorption, partially offset by higher variable costs.
The company reported a third-quarter net loss of $3.49 million, or $0.06 per share, and gross profit of $4.83 million. It completed a $46 million public equity offering in October to strengthen its balance sheet.
